Rituximab in critically ill patients

G Dimopoulos; A Armaganidis; G Poulakou; D K Matthaiou

Rituximab in critically ill patients

Minerva Anestesiol. 2013 Feb;79(2):185-93. Epub 2012 Nov 8.

Authors

G Dimopoulos¹, A Armaganidis, G Poulakou, D K Matthaiou

Affiliation

¹ Department of Critical Care, Medical School, University of Athens, Attikon University Hospital, Athens, Greece. [email protected]

PMID: 23135691

Abstract

Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Murine-Derived / adverse effects
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Critical Care
Critical Illness* / mortality
Graft vs Host Disease / complications
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / mortality
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use*
Infections / complications
Off-Label Use
Organ Transplantation
Rituximab

Substances

Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab